Entries by Dan Zapata

La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer

SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Darryl Wellinghoff as Chief Commercial Officer. “We are excited to welcome Darryl to La Jolla’s leadership team,” said George Tidmarsh, M.D., […]

La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, […]

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018

SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2018. For the three months ended September 30, 2018, GIAPREZA™ (angiotensin II) net […]

La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018

SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it will release its third quarter 2018 financial results on Wednesday October 24, 2018 and will host a webcasted conference call at 4:30 […]

La Jolla Pharmaceutical Company Announces Receipt of New Technology Add-on Payment Coverage for GIAPREZA

SAN DIEGO – August 3, 2018 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for […]

La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018

SAN DIEGO – August 1, 2018 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it will release its second quarter 2018 financial results on Wednesday, August 8, 2018 and will host […]

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has closed a $125 million royalty […]

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for […]